We sought to identify candidate driver events for patients with grade III ER+HER2−tumors based on treatment‐naive primary (n = 270) and post‐treatment metastatic diseases (n = 243) from MSKCC cohort. The gene discussed is ESR1; the disease is metastatic neoplasm.